TAS::75 0849::TAS THE MAIN TECHNICAL OBJECTIVE OF THIS CONTRACT IS TO GENERATE

Information

• Research Project
• 8164744

• ApplicationId

  8164744

• Core Project Number

  261201000094C-0-0-1

• Full Project Number

  261201000094C-0-0-1

• Serial Number

  0

• FOA Number

• Sub Project Id

• Project Start Date

  9/30/2010 - 14 years ago

• Project End Date

  6/30/2011 - 13 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2010

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• CANCER THERAPEUTICS LABORATORIES, INC.

In the last decade, monoclonal antibody immunotherapy has established itself as a front-line treatment of human cancer. One such antibody, Erbituz (cetuzimab), has been used to treat epidermal growth factor receptor positive (EGFR+) tumors due to its ability to inhibit tumor growth by blocking EGFR signaling required for cell proliferation. In this proposal, a generic anticody, designated ch225, will be generated to provide the medical community with a cost effective alternative product for Erbitux.

IC Name

• Activity

  N43

• Administering IC

  CA

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  299456

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  395

• Ed Inst. Type

• Funding ICs

  NCI:299456\

• Funding Mechanism

  Contracts, Extramural

• Study Section

• Study Section Name

• Organization Name

  CANCER THERAPEUTICS LABORATORIES, INC.

• Organization Department

• Organization DUNS

  137358805

• Organization City

  LOS ANGELES

• Organization State

  CA

• Organization Country

  UNITED STATES

• Organization Zip Code

  900890110

• Organization District

  UNITED STATES